ABCB5 and colonic neoplasm: Furthermore, the combined drug treatment caused 22-fold induced expression of miRNA522-5p, and this miRNA reverses drug resistance of doxorubicin-induced HT29 colon cancer cell by targeting ABCB5 [91].